11 results about "Acidum Nicotinicum" patented technology

The application discloses a nitrile hydratase mutant and application thereof in synthesis of nicotinamide, and belongs to the field of biological catalysis. Am NHase-beta-I106A / K19D / gamma-R8S as a catalyst, 300 g / L of 3-cyanopyridine is converted to obtain 348.5 g / L of nicotinamide under the conditions of 30 DEG C and pH 7.0 for 5 h, while the unmodified nitrile hydratase Am The nitrile hydratase catalyzes generation of nicotinamide to be only 206.3 g / L, and the conversion rate is increased from the original 58.6 % to 99 %. The application further provides a process for preparing immobilized cells from whole cells, which can significantly reduce generation of nicotinic acid byproducts while maintaining high conversion rate, is suitable for industrial amplification production, and provides an excellent enzyme catalyst and process for efficient and green synthesis of nicotinamide.

The present application belongs to genetic engineering, and particularly relates to a recombinant Lactobacillus plantarum with high yield of nicotinamide mononucleotide (NMN), a construction method and application. The recombinant Lactobacillus plantarum is obtained by overexpressing endogenous nicotinic acid phosphoribosyltransferase genes pncB1 and / or pncB2 in a host strain. The present application first constructs a strain capable of efficiently synthesizing NMN by taking Lactobacillus plantarum as a chassis, wherein the endogenous NMN synthesis pathway is directly strengthened by specifically expressing endogenous nicotinic acid phosphoribosyltransferase pncB1 and pncB2, so that the yield of Lactobacillus plantarum NMN is greatly improved. The endogenous nicotinic acid phosphoribosyltransferase of Lactobacillus plantarum is modified by using genetic engineering technology, and the problems of weak expression capacity of exogenous genes and substrate absorption and conversion are successfully solved, thereby providing a feasible solution for NMN production of other probiotics.

The application discloses a kind of by genome integration overexpression nicotinic acid phosphoribosyltransferase gene PncB, Nicotinic acid nucleotide adenylyltransferase gene NadD, Quinoline synthase gene NadA, Quinolinic acid phosphoribosyltransferase gene NadC, NAD+ synthetase NadE, NAD+ synthetase gene in Francisella tularensis FtNadE Method for obtaining stable high-yield β-nicotinamide mononucleotide (NMN) engineering strain by one or two genes in and applying it to fermentation production of NMN, and optimal high-yield strain B. subtilis PncB-NadD 5L fermenter batch feeding fermentation NMN yield can reach 4.547 g / L, compared with chassis strain Bacillus subtilis WB600 yield 1.034 g / L is increased by 339.75%. The problem of unstable performance of engineering strain is solved, and the production performance of strain NMN is improved, which has high industrial application value.

The purpose of the present invention is to provide a control agent and a control method that immediately control pests including gastropods and annelid worms, and are highly safe for humans, livestock, pet animals, and birds. The present invention provides a pest control agent which contains nicotinic acid or a derivative thereof as an active ingredient. The nicotinic acid or a derivative thereof is preferably nicotinic acid or nicotinic acid amide, and is preferably a mixture that contains at least both nicotinic acid and nicotinic acid amide. The dosage form of the control agent is preferably any one of a liquid agent, a stock solution-spraying agent, an aerosol agent, a solid agent, a tablet, a powder agent, a granule agent, a bait agent, and an agent to be used by impregnation. The dosage form preferably contains 0.001-30 wt% of nicotinic acid or a derivative thereof. The present invention also provides a pest control method in which a stock powder or a stock solution of the pest control agent is diluted with water so as to be 1-100,000 ppm, and then sprayed or impregnated for use.

FIELD: biotechnology.SUBSTANCE: modified composition of a nutrient medium for inducing the formation of soybean regenerated plants in vitro, including ammonium nitrate (NH4NO3) – 1650 mg / l; potassium nitrate (KNO3) – 1900 mg / l; calcium chloride dihydrate (CaCl2×2H2O) – 440 mg / l; magnesium sulfate (MgSO4×7H2O) – 370 mg / l; potassium phosphate (KH2PO4) – 170 mg / l; disodium salt of ethylenediaminetetraacetic acid (Na2 EDTA) – 37.3 mg / l; ferrous sulfate (FeSO4×7H2O) – 27.95 mg / l; boric acid (H3VO3) – 6.2 mg / l; manganese sulfate (MnSO4×4H2O) – 22.3 mg / l; zinc sulfate (ZnSO4×H2O) – 8.6 mg / l; sodium molybdate (Na2MoO4×2H2O) – 0.25 mg / l; copper sulfate (CuSO4×5H2O) – 0.025 mg / l; thionyl chloride (CoCl2×H2O) – 0.025 mg / l; agar-agar – 7000 mg / l, according to the invention the following components are additionally introduced: glycine – 1.0 mg / l; mesoinositol – 120 mg / l; ascorbic acid – 3.0 mg / l; nicotinic acid – 1.0 mg / l; pyridoxine-HCl – 1.5 mg / l; thiamine-HCl – 1.0 mg / l; biotin – 0.03 mg / l; sucrose – 25000 mg / l; 6-BAP – 1.0 mg / l; indole-butyric acid (IBA) – 1.5 mg / l; starch – 9000 mg / l; activated carbon – 3.0 mg / l; water is the rest.EFFECT: expanding the range of nutrient medium compositions for inducing the formation of soybean regenerated plants in vitro.1 cl, 3 tbl

This utility model discloses a double-layer material filling device for nicotinic acid sustained-release tablets, relating to the technical field of material filling devices. It includes a base, with a U-shaped support chamber fixedly connected to the top of the base via a lifting mechanism. The inner walls at both ends of the U-shaped support chamber have first limiting grooves and are slidably connected to U-shaped support seats. The top two ends of the U-shaped support seats are fixedly connected to a drug storage tank and a coating storage tank. The base provided by this utility model efficiently fills the double-layer material while simultaneously protecting the core drug layer and the sustained-release coating layer material stored inside. This solves the problems of existing nicotinic acid sustained-release tablets lacking professional filling devices during the filling process, hindering efficient and rapid filling, and lacking corresponding auxiliary protection for the core drug layer and the sustained-release coating layer material during the filling process.

The application discloses a synthetic method of flonicamid, and belongs to the technical field of organic synthesis. 4-trifluoromethyl nicotinic acid and aminoacetonitrile hydrochloride are reacted in the presence of a mixed catalytic system, a dichloromethane and water mixed system is used for refluxing, water is added for crystallization, and then filtering and drying are carried out to obtain white crystal flonicamid product, the purity of which can reach more than 99.0%, and the product is stored in a dry and sealed manner. The method has the advantages of simple operation, less reaction by-products, high product purity and low cost, and has great competitiveness in the market.

The application provides a preparation method of high-purity nicotinamide. The method comprises the following steps: mixing a solution containing nicotinamide and nicotinic acid with an alkali to obtain a mixed solution; wherein the alkali comprises one or more of alkali metal hydroxide, alkali metal carbonate and alkali metal bicarbonate; and concentrating and crystallizing the mixed solution to obtain high-purity nicotinamide. The method can reduce the content of nicotinic acid in nicotinamide and improve the purity of nicotinamide.

The application discloses an EGCG-nicotinic acid co-crystal as well as a preparation method and application thereof, and belongs to the technical field of drug co-crystals. The method comprises the following steps: EGCG and nicotinic acid are mixed according to a molar ratio of 1-5:1-5, and are ground; or, EGCG and nicotinic acid are mixed according to a molar ratio of 1-5:1-5, and are then dissolved by using water, water is removed, and grinding is performed; or, EGCG and nicotinic acid are mixed according to a molar ratio of 1-5:1-5, are then dissolved by using water, are frozen, water is removed, and grinding is performed; or, EGCG and nicotinic acid are mixed according to a molar ratio of 1-5:1-5, and an EGCG-nicotinic acid co-crystal is obtained. The EGCG-nicotinic acid co-crystal prepared by the application has significantly improved tyrosinase inhibition performance, antioxidant performance, antibacterial performance and transdermal rate; and the problem of low stability and low water solubility of EGCG in the prior art is solved.

This invention relates to a method for preparing 2-(methylsulfonyl)nicotinaldehyde, belonging to the field of organic synthesis technology. The invention includes the following steps: Under a protective atmosphere, 2-mercaptonicotinic acid and potassium carbonate are dissolved in an organic solvent, and iodomethane is added to react, yielding a white solid methyl 2-methylthionicotinic acid ester; the obtained methyl 2-methylthionicotinic acid ester is dissolved in acetic acid with sodium tungstate hydrate, and an oxidizing agent is added at -5℃ to 5℃, the reaction is carried out at room temperature, and the product is collected to obtain a white solid methyl 2-(methylsulfonyl)nicotinic acid ester; Under a protective atmosphere, the obtained methyl 2-(methylsulfonyl)nicotinic acid ester is dissolved in tetrahydrofuran, and a reducing agent is added and stirred to react at -83℃ to -73℃, after the reaction is completed, the product is collected to obtain 2-(methylsulfonyl)nicotinaldehyde. The purity of the 2-(methylsulfonyl)nicotinaldehyde obtained by this invention is 97%-99%, and the overall yield is above 70%.